India’s first indigenously developed vaccine for cervical cancer prevention is to be launched Thursday
India’s first indigenously developed Human Papilloma Virus (HPV) vaccine for the prevention of cervical cancer will be launched here on Thursday, officials said on Wednesday, as the Drugs Controller General of India (DCGI) last month sold the Serum Institute of India to the market. authorization was granted. SII) to make an indigenously developed vaccine against cervical cancer.
Union Science and Technology Minister Jitendra Singh will launch the vaccine at IIC Delhi. SII CEO Adar Poonawalla will be present at the event, officials said.
According to officials, the qHPV vaccine CERVAVAC has demonstrated a strong antibody response that is about 1,000-fold higher for all targeted HPV types and across all doses and age groups.
Cervical cancer is the second most frequent cancer in women in the age group of 15 to 44 years in India.
Prakash Kumar Singh, Director (Government and Regulatory Affairs) at Serum Institute, applied for market authorization to DCGI following the recommendation of CDSCO’s Subject Expert Committee (SEC) on COVID-19 on June 15. she came. qHPV Phase II and III clinical trials were completed in collaboration with the Department of Biotechnology under the Ministry of Science and Technology to ensure its early availability.